They showed that GLP-1-Fc-FGF21 D1 performed better than both comparators in reducing liver steatosis, inflammation, and hepatocellular ballooning, indicating another potential dual-acting agent in the pharmacological pipeline of NAFLD [48]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.